Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : EpimAb Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Medigene & EpimAb Partner for TCR-Guided T Cell Engagers
Details : Through the partnership, both companies will focus on researching and developing off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 27, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : EpimAb Biotherapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : $435.0 million
Deal Type : Licensing Agreement
Gilead Taps German biotech Tubulis for Solid Tumor ADC Development Deal Worth up to $465M
Details : The agreement aims to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target using Tubulis’ proprietary Tubutecan and Alco5 platforms.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : $20.0 million
March 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Gilead Sciences
Deal Size : $435.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Sofinnova Partners
Deal Size : $21.7 million
Deal Type : Financing
DISCO Pharmaceuticals Launches as Surfaceome Company with EUR 20 Million in Seed Funding
Details : The net proceeds will be used for the development of new treatment modalities such as antibody-drug conjugates (ADCs) and bi-specific antibodies, in oncology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Sofinnova Partners
Deal Size : $21.7 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioMed X Launches New T Cell Immunology Discovery Platform
Details : A new technology developed by BioMed X in collaboration with Janssen functionally identifies and validates T cell target antigens, making it a powerful tool for T Cell Therapy and immunology discovery.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : BAMF
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration between BAMF and ITM aims to leverage the respective strengths of both organizations to provide novel treatment options using radioisotopes that potentially improve clinical outcomes and quality of life for patients living with cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 09, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : BAMF
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : CureVac
Deal Size : $33.3 million
Deal Type : Acquisition
Details : An additional application of Frame’s technology is the development of personalized cancer vaccines, thereby leveraging the full antigenic potential of a tumor. CureVac will refocus development of personalized cancer vaccines on an mRNA modality.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : CureVac
Deal Size : $33.3 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Collaboration
Details : BioNTech will acquire Medigene’s next generation preclinical TCR program, which combines TCR-4 of Medigene’s MDG10XX program targeting PRAME with Medigene’s proprietary PD1-41BB switch receptor technology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $29.1 million
February 21, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Byondis
Deal Size : Undisclosed
Deal Type : Agreement
Byondis , Glycotope Enter Platform Access Agreement Discovery and Development
Details : Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs). Specific financial terms have not been disclose...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 27, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Byondis
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Cellectis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
SIRION Biotech GmbH Licensed Its LentiBOOST™ Transduction Technology to Cellectis
Details : Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 01, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Cellectis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Evotec and Bristol Myers Squibb to Extend Their Targeted Protein Degradation Partnership
Details : The partnership leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with the integrated data analysis platform PanHunter.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration